Relay Therapeutics, Inc. Common Stock
RLAY
RLAY: Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
moreShow RLAY Financials
Recent trades of RLAY by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel Goldman House / D | Sale $1,001 - $15,000 | Jul. 12, 2023 |
Recently reported changes by institutional investors
Quarterly net insider trading by RLAY's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Dec. 20, 2022
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Mar. 02, 2021
Federal grants, loans, and purchases
Followers on RLAY's company Twitter account
Number of mentions of RLAY in WallStreetBets Daily Discussion
Recent insights relating to RLAY
Recent picks made for RLAY stock on CNBC
ETFs with the largest estimated holdings in RLAY
Flights by private jets registered to RLAY